Exact Sciences stock is hot, ‘The Street’ says

Anticipating strong quarterly earnings for Exact Sciences, TheStreet believes the Cologuard-maker is in line for growth.

Advertisement

Here’s what you should know:

1. Exact reports its earnings Aug. 1.

2. The company’s stock has jumped 23 percent since the start of the year.

3. Six analysts have awarded Exact a “buy” rating.

4. Baird’s Catherine Schulte said, “We believe [Exact] is positioned to deliver on/exceed its 2018 guidance, with marketing campaigns, salesforce expansion and health system penetration all potentially helping [the second half] and beyond.” She also predicted Exact will hit around $1 billion in revenues in two years.

More articles on gastroenterology:
Key Surgical, ModMed & more — 3 GI company key notes
10 things to know about ASC coding audits
GI residents earn over $64K — Here’s which specialties rake in more

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.